H
Hagen Kennecke
Researcher at University of British Columbia
Publications - 12
Citations - 433
Hagen Kennecke is an academic researcher from University of British Columbia. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 11, co-authored 12 publications receiving 372 citations. Previous affiliations of Hagen Kennecke include BC Cancer Agency & Vancouver Coastal Health.
Papers
More filters
Journal ArticleDOI
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases
Dmitry Turbin,Dmitry Turbin,Samuel Leung,Samuel Leung,Maggie C.U. Cheang,Maggie C.U. Cheang,Hagen Kennecke,Hagen Kennecke,Kelli Montgomery,Steven McKinney,Diana O. Treaba,Niki Boyd,Lynn C. Goldstein,Sunil Badve,Allen M. Gown,Matt van de Rijn,Torsten O. Nielsen,Torsten O. Nielsen,C. Blake Gilks,C. Blake Gilks,David G. Huntsman,David G. Huntsman +21 more
TL;DR: Fully automated quantitation of ER immunostaining yields results that do not differ from human scoring against both biochemical assay and patient outcome gold standards.
Journal ArticleDOI
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus
Simron Singh,Sylvia L. Asa,C. Dey,Hagen Kennecke,David Laidley,Calvin Law,Timothy R. Asmis,David Chan,Shereen Ezzat,Rachel Anne Goodwin,Ozgur Mete,Janice L. Pasieka,Juan Andres Rivera,R. Wong,Eva Segelov,Daniel Rayson +15 more
TL;DR: Consensus recommendations are devised to guide state of the art clinical management of GI-NETs, including new level 1 evidence for novel therapies, including telotristat etiprate (TELESTAR), lanreotide (CLARINET), everolimus (RADIant-2; RADIANT-4) and peptide receptor radionuclide therapy (PRRT; NETTER-1).
Journal ArticleDOI
Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
Hagen Kennecke,Hagen Kennecke,Heather L. McArthur,Ivo A. Olivotto,Ivo A. Olivotto,Caroline Speers,Chris Bajdik,Stephen Chia,Stephen Chia,Susan Ellard,Susan Ellard,B. Norris,B. Norris,Malcolm Hayes,Jeff Barnett,Karen A. Gelmon,Karen A. Gelmon +16 more
TL;DR: Adjuvant aromatase inhibitors (AIs), instead of or after tamoxifen, are effective in decreasing recurrence in postmenopausal women with estrogen receptor (ER)‐positive breast cancer.
Journal ArticleDOI
αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis
K. David Voduc,Torsten O. Nielsen,Charles M. Perou,J. Chuck Harrell,Cheng Fan,Hagen Kennecke,Andy J. Minn,Vincent L. Cryns,Maggie C.U. Cheang +8 more
TL;DR: αB-crystallin is a promising biomarker to identify breast cancer patients at high risk for early relapse in the brain, independent of estrogen receptor and human epidermal growth factor receptor-2 status.
Journal ArticleDOI
Patterns of relapse in breast cancer: changes over time
TL;DR: A significant decline in 5-year cumulative incidence of metastases and an increase in the proportion of NBM as first site of metastasis were observed between earlier and later cohorts, reflecting the need for more successful adjuvant treatment options for aggressive breast cancer subtypes which are more likely to present with early spread to visceral organs.